This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients

This study has been completed.
Information provided by:
Eli Lilly and Company Identifier:
First received: April 25, 2007
Last updated: November 23, 2010
Last verified: November 2010
The purpose of the study is to compare the response rates for prostate cancer patients taking chemotherapy plus enzastaurin versus chemotherapy plus placebo.

Condition Intervention Phase
Prostate Cancer Drug: enzastaurin Drug: placebo Drug: docetaxel Drug: prednisone Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study With and Without Enzastaurin in Combination With Docetaxel and Prednisone, Followed By Enzastaurin Maintenance as First-Line Treatment in Hormone Refractory Metastatic Prostate Cancer Patients

Resource links provided by NLM:

Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • To determine response rate of enzastaurin given with chemotherapy in prostate cancer patients when they have taken enzastaurin for a maximum of 3 years [ Time Frame: 3 years ]

Secondary Outcome Measures:
  • To assess rate of PSA level decline of greater than or equal to 30% [ Time Frame: 3 months ]
  • Progression free survival [ Time Frame: baseline to measured progressive disease ]
  • Adverse events and safety [ Time Frame: every cycle ]
  • To characterize the pharmacokinetics of enzastaurin [ Time Frame: cycle 1, cycle 2 ]
  • Assess tumor biomarkers [ Time Frame: baseline, cycle 2, at 36 months ]

Enrollment: 101
Study Start Date: June 2007
Study Completion Date: June 2010
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: enzastaurin
1125 mg loading dose then 500 mg, oral, daily, until disease progression, toxicity, or maximum 3 years
Other Name: LY317615
Drug: docetaxel
75 mg/m2, IV, q 21 days, six 21 day cycles, maximum 10 cycles
Drug: prednisone
5 mg, oral, BID, six 21 day cycles
Placebo Comparator: B Drug: placebo
oral, daily
Drug: docetaxel
75 mg/m2, IV, q 21 days, six 21 day cycles, maximum 10 cycles
Drug: prednisone
5 mg, oral, BID, six 21 day cycles


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • You are at least 18 years old.
  • You live close enough to the doctor's office to attend all of your required visits.
  • You have not been treated with chemotherapy for your prostate cancer.
  • Your organs must be functioning properly.

Exclusion Criteria:

  • You are unable to swallow pills.
  • You have another serious illness besides your prostate cancer.
  • You have taken another experimental drug within the last 30 days.
  • You have a serious heart condition.
  • You are receiving another anti-cancer therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00466440

  Show 28 Study Locations
Sponsors and Collaborators
Eli Lilly and Company
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Chief Medical Officer, Eli Lilly Identifier: NCT00466440     History of Changes
Other Study ID Numbers: 11311
H6Q-MC-S032 ( Other Identifier: Eli Lilly and Company )
Study First Received: April 25, 2007
Last Updated: November 23, 2010

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal processed this record on August 18, 2017